MedTrace Logo

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT07570823 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Conditions

  • DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG

SCTB35 injection

SCTB35 will be subcutaneously administered at a dose as specified

DRUG

Rituxumab

Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.

DRUG

Gemcitabine

Participants will receive IV gemcitabine administration for up to 8 cycles.

DRUG

Oxaliplatin

Participants will receive IV oxaliplatin administration for up to 8 cycles.

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-11-30
Completion
2029-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07570823 on ClinicalTrials.gov